Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Immunogenicity and Safety of GSK Biologicals’ Influenza Vaccine Versus a Licensed Comparator in Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02434770).
- Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer’s Prevenar 13™Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration…
- Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals’ Candidate Influenza Vaccine in Healthy Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe: primary endpoint results, effect estimate…
- Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.: primary endpoint results, effect…
- Immunogenicity and Safety Study of Booster Dose of GSK Biologicals’ IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older: primary endpoint results, effect estimate…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: primary endpoint results,…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults: primary endpoint results, effect…
- Immunogenicity and Safety Study of GSK Biologicals’ Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF)…
- Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00813904).
- Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity of GSK Biologicals’ Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity of Influenza Vaccinations: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of Influenza Vaccinations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06518577).
- Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04026178).
- Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04523324).
- Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.: primary endpoint results, effect estimate with confidence interval,…
- Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above: primary endpoint results, effect estimate with confidence interval,…
- Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.: Complete Statistical AnalysisIndependent statistical analysis of Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161): Complete Statistical AnalysisIndependent statistical analysis of Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma: primary endpoint results, effect estimate with confidence interval,…
- Immunomodulatory Properties of Ketamine in Sepsis: Complete Statistical AnalysisIndependent statistical analysis of Immunomodulatory Properties of Ketamine in Sepsis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01089361).
- Immunonutrition for Diabetic Foot Ulcers: Complete Statistical AnalysisIndependent statistical analysis of Immunonutrition for Diabetic Foot Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05281562).
- Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab: Complete Statistical AnalysisIndependent statistical analysis of Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immunotherapy Study for Patients With Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Immunotherapy Study for Patients With Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02054520).
- Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions: Complete Statistical AnalysisIndependent statistical analysis of Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04936230).
- IMOVAIndependent statistical analysis of Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- IMPACTIndependent statistical analysis of An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- IMPACTIndependent statistical analysis of Deprescribing Potentially Inappropriate Medications in the Emergency Department for Persons Living With Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IMPaCTIndependent statistical analysis of CGM Use in Poorly Controlled Youth With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04721145).
- IMPACTIndependent statistical analysis of Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IMPACTIndependent statistical analysis of IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…